The FDA approved Moderna’s mRNA-based seasonal influenza vaccine, mRNA-1010 (mFLUSIVA), marking the first approval for an mRNA flu shot in the US. The decision followed a unanimous vote by the Vaccines and Related Biological Products Advisory Committee (VRBPAC) that benefits outweighed risks for adults aged 50–64.